A rational drug design approach involving transposition of functional groups from SRIF into a reduced size cyclohexapeptide template has led to the discovery of SOM230, a novel, stable cyclohexapeptide somatostatin mimic which exhibits unique high affinity binding to human somatostatin receptors (sst1-5). This unique receptor subtype binding profile, in particular the exceptional high affinity binding to sst5, led to SOM230 being approved by EMEA and FDA in 2012 as the first effective pituitary directed therapeutic modality for Cushing's disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2533/chimia.2014.483 | DOI Listing |
Publication Analysis
Top Keywords
therapeutic modality
8
modality cushing's
8
cushing's disease
8
high affinity
8
affinity binding
8
som230 therapeutic
4
disease rational
4
rational drug
4
drug design
4
design approach
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!